Holen Sie sich die Stockscreener-App
147.12
1.33%
1.93
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$145.19
Offen:
$146.96
24-Stunden-Volumen:
1.65M
Relative Volume:
0.18
Marktkapitalisierung:
$362.97B
Einnahmen:
$65.51B
Nettoeinkommen (Verlust:
$8.93B
KGV:
41.40
EPS:
3.5532
Netto-Cashflow:
$14.12B
1W Leistung:
+1.04%
1M Leistung:
+1.53%
6M Leistung:
+27.42%
1J Leistung:
+75.31%
1-Tages-Spanne:
$145.91
$147.79
1-Wochen-Bereich:
$141.58
$152.34
52-Wochen-Spanne:
$82.01
$156.92
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
147.12 | 362.97B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,264.55 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.10 | 619.58B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.56 | 504.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
151.35 | 287.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-08-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-08-12 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2026-05-06 | Fortgesetzt | Citigroup | Neutral |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-02-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-13 | Fortgesetzt | Citigroup | Neutral |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? - The Motley Fool
Goldman Sachs Adjusts Price Target on Merck & Co to $155 From $160 - marketscreener.com
Milestone Asset Management LLC Sells 9,248 Shares of Merck & Co., Inc. $MRK - MarketBeat
8,527 Shares of Merck & Co., Inc. $MRK Acquired by Neumann Capital Management LLC - MarketBeat
Merck & Co., Inc. $MRK Stock: State of Alaska Department of Revenue Reduces Stake - MarketBeat
18,326 Merck & Co., Inc. $MRK Shares Sold by Ninety One UK Ltd - MarketBeat
1,133,024 Merck & Co., Inc. $MRK Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Curated Wealth Partners LLC Sells 127,541 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine - Yahoo Finance
Merck (NYSE: MRK) 2026 notes are slated for voluntary withdrawal from NYSE listing. - Stock Titan
Merck & Co., Inc. (MRK) Options Chain - Yahoo! Finance Canada
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock - Yahoo Finance
VMS Asset Management Limited Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Position Lessened by HBW Advisory Services LLC - MarketBeat
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Western Financial Corp CA Acquires 29,043 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Acquired by Strategy Asset Managers LLC - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Godsey & Gibb Inc. - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Stock Jumps 3.6%Still a Buy? - MarketBeat
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? - Zacks Investment Research
History Says This Is Hands-Down the Best ETF to Buy if a Bear Market Is Coming - The Motley Fool
Merck (MRK) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Merck (MRK) Dips More Than Broader Market: What You Should Know - Yahoo Finance
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Here's What to Expect From Merck & Co.'s Next Earnings Report - Yahoo Finance
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors - Yahoo Finance
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Zacks Investment Research
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
Merck's experimental eye drug meets goal in trial, but raises safety concerns (MRK:NYSE) - Seeking Alpha
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell? - The Motley Fool
Merck & Co., Inc. $MRK Stock Holdings Raised by Stokes Capital Advisors LLC - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Castle Rock Wealth Management LLC - MarketBeat
MERCK & CO INC MERCK & CO ORD (0QAH.L) Q2 FY2026 earnings call transcript - Yahoo Finance
11,142 Merck & Co., Inc. $MRK Shares Bought by Wedmont Private Capital - MarketBeat
Merck & Co., Inc. $MRK Position Reduced by Brown Shipley& Co Ltd - MarketBeat
19,456 Merck & Co., Inc. $MRK Shares Sold by Douglas Lane & Associates LLC - MarketBeat
Merck & Co., Inc. $MRK Position Raised by Mn Services Vermogensbeheer B.V. - MarketBeat
Farther Finance Advisors LLC Acquires 11,956 Shares of Merck & Co., Inc. $MRK - MarketBeat
Rep. Maria Elvira Salazar Sells Off Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Is Merck (NYSE:MRK) Gaining Fresh Momentum After Latest Target Boost? - Kalkine Media
Quintet Private Bank Europe S.A. Grows Stock Position in Merck & Co., Inc. $MRK - MarketBeat
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
INVA vs. MRK: Which Stock Is the Better Value Option? - Zacks Investment Research
Masterson recognized by Merck and AABP - High Plains Journal
Merck & Company, Inc. Stock 12‑Month Price Target Raised to $157.48, Implies 10% Upside - TradingView
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merck Co Inc-Aktie (MRK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CHIRFI GUINDO | Officer |
Aug 13 '26 |
Proposed Sale |
135.00 |
10,000 |
1,350,000 |
0 |
| JENNIFER L ZACHARY | Officer |
Aug 12 '26 |
Proposed Sale |
133.46 |
80,315 |
10,718,495 |
0 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 12 '26 |
Proposed Sale |
131.63 |
11,699 |
1,539,992 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 12 '26 |
Sale |
131.63 |
11,699 |
1,539,992 |
110,167 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Option Exercise |
109.78 |
54,927 |
6,029,637 |
125,824 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Sale |
133.46 |
80,315 |
10,718,495 |
45,509 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 11 '26 |
Sale |
131.76 |
12,837 |
1,691,426 |
121,866 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 11 '26 |
Proposed Sale |
131.76 |
12,837 |
1,691,426 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 10 '26 |
Sale |
130.43 |
20,784 |
2,710,951 |
134,703 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 10 '26 |
Proposed Sale |
130.43 |
20,784 |
2,710,951 |
0 |
0.65%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):